Lipella pharmaceuticals announces completion of site initiation visit for phase 2a trial of lp-310 in oral lichen planus

Clinical testing of lp-310 expected to commence in mid-2024 patient recruitment is underway for phase 2a multicenter, dose-ranging study pittsburgh, may 31, 2024 (globe newswire) -- lipella pharmaceuticals inc. (nasdaq: lipo) (“lipella,” “our,” “us” or the “company”), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announced the successful completion of its first site initiation visit (siv) for the phase 2a trial evaluating lp-310 in the treatment of oral lichen planus (olp). with clearance received from the central institutional review board (irb), the phase 2a trial is set to commence with site qualifications completed and patient recruitment underway.
LIPO Ratings Summary
LIPO Quant Ranking